LON:AERI

Aquila European Renewables Income Share Forecast, Price & News

GBX 1.02
0.00 (0.00 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
1.02
1.02
50-Day Range
1.02
1.10
52-Week Range
1.02
1.14
Volume145,911 shs
Average Volume225,583 shs
Market Capitalization£3.25 million
P/E RatioN/A
Dividend Yield4.88%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquila European Renewables Income and its competitors with MarketBeat's FREE daily newsletter.


About Aquila European Renewables Income

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aquila European Renewables Income (LON:AERI) Frequently Asked Questions

What stocks does MarketBeat like better than Aquila European Renewables Income?

Wall Street analysts have given Aquila European Renewables Income a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aquila European Renewables Income wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Is Aquila European Renewables Income a good dividend stock?

Aquila European Renewables Income pays an annual dividend of GBX 0.04 per share and currently has a dividend yield of 4.88%. AERI has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Aquila European Renewables Income's dividend history.

Who are some of Aquila European Renewables Income's key competitors?

What is Aquila European Renewables Income's stock symbol?

Aquila European Renewables Income trades on the London Stock Exchange (LON) under the ticker symbol "AERI."

How do I buy shares of Aquila European Renewables Income?

Shares of AERI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Aquila European Renewables Income's stock price today?

One share of AERI stock can currently be purchased for approximately GBX 1.02.

How much money does Aquila European Renewables Income make?

Aquila European Renewables Income has a market capitalization of £3.25 million.

How many employees does Aquila European Renewables Income have?

Aquila European Renewables Income employs 365 workers across the globe.

What is Aquila European Renewables Income's official website?

The official website for Aquila European Renewables Income is www.aquila-european-renewables-income-fund.com.

Where are Aquila European Renewables Income's headquarters?

Aquila European Renewables Income is headquartered at 4301 Emperor Blvd Ste 400, Durham, North Carolina 27703-7615.

How can I contact Aquila European Renewables Income?

Aquila European Renewables Income's mailing address is 4301 Emperor Blvd Ste 400, Durham, North Carolina 27703-7615. The company can be reached via phone at 19192375300.


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.